Multiple sclerosis: Is there a risk of worsening after yellow fever vaccination?
Vaccination
multiple sclerosis
travel
yellow fever
yellow fever vaccination
Journal
Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
pubmed:
20
4
2021
medline:
28
1
2022
entrez:
19
4
2021
Statut:
ppublish
Résumé
Yellow fever vaccine (YFV) is not advised for multiple sclerosis (MS) patients because of the potential risk of post-vaccine relapses. To assess the risk of relapsing-remitting multiple sclerosis (RR-MS) worsening after YFV. Non-interventional observational retrospective, exposed/non-exposed cohort study nested in the French national cohort including MS. 128 RR-MS were included. The 1-year annualized relapse rate (ARR) following YFV did not differ between exposed: 0.219 (0.420) and non-exposed subjects: 0.208 (0.521) ( These results suggest that YFV does not worsen the course of RR-MS.
Sections du résumé
BACKGROUND
Yellow fever vaccine (YFV) is not advised for multiple sclerosis (MS) patients because of the potential risk of post-vaccine relapses.
OBJECTIVE
To assess the risk of relapsing-remitting multiple sclerosis (RR-MS) worsening after YFV.
METHODS
Non-interventional observational retrospective, exposed/non-exposed cohort study nested in the French national cohort including MS.
RESULTS
128 RR-MS were included. The 1-year annualized relapse rate (ARR) following YFV did not differ between exposed: 0.219 (0.420) and non-exposed subjects: 0.208 (0.521) (
CONCLUSION
These results suggest that YFV does not worsen the course of RR-MS.
Identifiants
pubmed: 33870792
doi: 10.1177/13524585211006372
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM